CTSA K12 Program at Harvard Medical School

哈佛医学院 CTSA K12 项目

• 批准号: 10621595
• 负责人: Karen K Miller
• 金额: $ 161.98万
• 依托单位: HARVARD MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-05-15 至 2028-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10621595
• 关键词: Academic Medical Centers; Academy; Clinical; Clinical Investigator; Clinical Research; Clinical Sciences; Communities; Competence; Dedications; Development; Educational Curriculum; Elements; Ensure; Environment; Funding; Future; Goals; Growth; Health; Human; Infrastructure; Leadership; Medical Research; Mentored Clinical Scientist Development Program; Mentors; Mentorship; National Center for Advancing Translational Sciences; Performance; Program Development; Research; Research Personnel; Scholars Program; Science; Time; Training; Translating; Translational Research; United States National Institutes of Health; Work; career; career development; catalyst; community engagement; diversity and inclusion; educational atmosphere; improved; innovation; interdisciplinary collaboration; medical schools; programs; success; translational pipeline; translational scientist; visiting scholar

PROJECT SUMMARY The goal of the Harvard Catalyst K12 program is to create an environment for early-stage clinical and translational (CT) investigators that facilitates their career development and encourages paradigm-shifting, diversity-focused interdisciplinary collaboration and team-based research approaches to advance CT science. Since its founding in 2008, the Harvard Catalyst KL2 program has served as the cornerstone across Harvard Medical School (HMS) and its affiliated academic medical centers for training our most outstanding early-stage CT investigators. Given the demonstrated success of the KL2 program since 2008, the new K12 program will build on the KL2 program's strengths. The new K12 program will specifically seek to help train and develop the future leaders of CT science by leveraging the Harvard Catalyst cores and integrating the scholars into the broader CT infrastructure at Harvard Catalyst and the CTSA consortium. In addition, through dedicated funding from the HMS-affiliated AMCs, the K12 program will continue to be paired with the Catalyst Medical Research Investigator (CMeRIT) program to further enrich the K12 learning environment. Moreover, through the continued growth and expansion of the Clinical and Translational Research Academy, a supporting infrastructural element of Harvard Catalyst, the K12 will create a community for CT investigators and enhance the transition to independence for all K awardees across HMS. Finally, the K12 program will work closely with the Harvard Catalyst Cores and other NIH-funded programs at HMS to enhance the research capability, competency and performance of all K12 awardees with a new focus on translational science. The overarching objective of the program is to ensure and nurture the sustainable careers of early-stage CT investigators and ultimately advance translational science. The K12 program will offer sustained protected time for scholars to advance their CT research, overseen by a primary mentor and co-mentor and now further enhanced by a dedicated mentorship committee, including a separate career mentor to provide outside input on broader career goals. Training will include the use of new courses and programs, including our monthly Translate Together curriculum, that covers the broad translational spectrum and focuses on developing innovative solutions that improve human health. It will also include the development of individualized career development programs, leadership training, visibility through participation in the national CTSA Visiting Scholar Program, and mentor/mentee training, to ensure the success of each scholar as a translational scientist as envisioned by NCATS. The K12 will also seek to educate scholars on the importance of community engagement for the execution of effective CT research to ensure the highest quality science can be completed. In a related context, building on our earlier success in improving the diversity of the KL2 program, we will continue several diversity and inclusion initiatives both to ensure that we have a vibrant and diverse group of scholars but also to ensure that all scholars are fully educated on diversity as a critical feature of all successful CT research endeavors.

项目总结 哈佛大学催化剂K12计划的目标是为早期临床和 促进其职业发展并鼓励范式转变的翻译(CT)调查人员， 注重多样性的跨学科协作和基于团队的研究方法，以促进CT科学的发展。 自2008年成立以来，哈佛Catalyst KL2计划一直是整个哈佛的基石 医学院(HMS)及其附属学术医学中心为我们培养早期最优秀的人才 CT调查员。鉴于KL2计划自2008年以来取得的成功，新的K12计划将 建立在KL2计划的优势之上。新的K12计划将特别寻求帮助培训和发展 通过利用哈佛催化剂核心并将学者整合到 哈佛催化剂和CTSA联盟更广泛的CT基础设施。此外，通过专门的资金 从HMS附属的AMC中，K12计划将继续与Catalyst Medical Research配对 调查员(CMeRIT)计划，进一步丰富K12学习环境。此外，通过继续 作为辅助基础设施的临床与翻译研究院的成长和扩张 作为哈佛催化剂的一部分，K12将为CT调查人员创建一个社区，并促进过渡 为HMS所有K获奖者的独立干杯。最后，K12项目将与哈佛大学密切合作 HMS的催化剂核心和其他由NIH资助的计划，以增强研究能力、能力和 所有K12获奖者的表现，并将新的重点放在翻译科学上。该计划的总体目标 该计划旨在确保和培育早期CT研究人员的可持续职业生涯，并最终推动 翻译科学。K12计划将为学者提供持续的保护时间来推进他们的CT 研究，由主要导师和联合导师监督，现在由专门的导师进一步加强 委员会，包括一名单独的职业导师，为更广泛的职业目标提供外部意见。培训将会 包括使用新的课程和计划，包括我们的每月一起翻译课程，其中包括 广泛的翻译范围，并专注于开发改善人类健康的创新解决方案。它 还将包括制定个性化的职业发展计划、领导力培训、知名度 通过参加国家CTSA访问学者计划和导师/学员培训，确保 每一位学者作为NCATS所设想的翻译科学家的成功。K12还将寻求教育 学者们强调社区参与对执行有效的CT研究的重要性，以确保 可以完成最高质量的科学。在相关的背景下，在我们早先成功改善 KL2计划的多样性，我们将继续实施几项多样性和包容性倡议，以确保我们 拥有一个充满活力和多样化的学者群体，但也要确保所有学者都接受过关于多样性的充分教育 作为所有成功的CT研究努力的关键特征。